FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/New Clinical Trial Investigates Tirzepatide for Bowel Frequency in IPAA Patients
研究ライブラリに戻る

New Clinical Trial Investigates Tirzepatide for Bowel Frequency in IPAA Patients

November 20, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

New Clinical Trial Investigates Tirzepatide for Bowel Frequency in IPAA Patients

A new clinical trial has been launched to explore whether tirzepatide, a peptide therapy used for diabetes management, can effectively reduce bowel frequency in patients with ileal pouch-anal anastomosis (IPAA). The study, registered on ClinicalTrials.gov under the identifier NCT07756359, aims to determine if tirzepatide outperforms standard anti-diarrheal treatments like loperamide and diphenoxylate/atropine in managing chronic bowel issues.

Background

Ileal pouch-anal anastomosis (IPAA) is a surgical procedure commonly performed for patients with ulcerative colitis or familial adenomatous polyposis. While this surgery can alleviate symptoms of these conditions, it often leads to complications such as increased bowel frequency and diarrhea. Current treatments like loperamide are limited in their effectiveness and may not provide long-term relief.

Tirzepatide is a dual GIP and GLP-1 receptor agonist that has shown promise in managing type 2 diabetes by improving blood sugar control and reducing body weight. Researchers believe its mechanism of action might also benefit patients with IPAA, as it could help regulate gastrointestinal motility and reduce bowel frequency.

Key Details

The trial is being conducted at the University of North Carolina, Chapel Hill, under the sponsorship of the institution's medical research department. The study will recruit participants who have undergone IPAA surgery and are experiencing chronic high bowel frequency despite standard anti-diarrheal therapy. Participants will be randomly assigned to receive either tirzepatide or a combination of loperamide and diphenoxylate/atropine.

The primary objective is to evaluate whether tirzepatide can significantly reduce the number of daily bowel movements compared to current treatments. Secondary objectives include assessing patient quality of life, symptom severity, and overall treatment satisfaction. Participants will be required to visit the clinic five times over a period of several months and complete daily questionnaires about their symptoms.

This research is crucial for the peptide community because it explores new therapeutic avenues for conditions that are currently difficult to manage with existing treatments. The potential benefits of tirzepatide in this context could offer hope to patients suffering from chronic bowel issues following IPAA surgery, a condition that significantly impacts quality of life.

Key Takeaways

  • New Treatment Option: This trial investigates the use of tirzepatide as a novel treatment for managing high bowel frequency after IPAA.
  • Comparative Study Design: Participants will be compared against standard anti-diarrheal medications to assess relative efficacy and safety.
  • Patient-Centric Approach: The study aims to improve patient quality of life by addressing chronic symptoms that impact daily living.
  • Peptide Therapy Potential: This research highlights the expanding role of peptide therapies beyond their traditional applications in diabetes management.

What This Means

For clinicians, researchers, and patients alike, this trial represents a significant step forward in understanding how tirzepatide might be repurposed to address gastrointestinal complications following IPAA surgery. If successful, it could pave the way for new treatment protocols that offer more effective relief from chronic bowel issues.

The findings of this study will contribute valuable insights into the broader landscape of peptide therapy research and its potential applications in managing complex medical conditions beyond diabetes. As such, it underscores the importance of continued exploration into the diverse therapeutic benefits of peptides across various medical specialties.

---

Source: ClinicalTrials.gov — Published 2026-11-18

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。